Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected south african children

AIDS Research and Human Retroviruses

Volumn 26, Issue 6, 2010, Pages 613-619

  Viljoen, Michelle ^a   Gous, Hermien ^b   Kruger, Herculina S ^a   Riddick, Alison ^b   Meyers, Tammy M ^b,c   Rheeders, Malie ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; COTRIMOXAZOLE; EFAVIRENZ; LAMIVUDINE; MIDAZOLAM; PARACETAMOL; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIMETHOPRIM; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ADOLESCENT; AFRICAN AMERICAN; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLOOD SAMPLING; CHILD; EVENING DOSAGE; FEMALE; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; AMBULATORY CARE; CHEMISTRY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; PLASMA; SOUTH AFRICA; TIME; VIROLOGY;

ADOLESCENT; AMBULATORY CARE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, LIQUID; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PLASMA; SOUTH AFRICA; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 77954188085     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0200     Document Type: Article

References (28)

1. UNAIDS: UNAIDS 2008 report on the global AIDS epidemic. Geneva, Switzerland, 2008.
2. National Department of Health South Africa: Section: 10 Antiretroviral therapy (ART). In: Guidelines for the Management of HIV-Infected Children, 1st ed. Jacana Media, Pretoria, 2005, pp. 1-148.
3. Stocrin: Stocrin (efavirenz) product information leaflet. Halfway House, South Africa: Merck Sharp & Dohme (Pty) Ltd, May 2004.
4. Pereira SA, Branco T, Caixas U, et al.: Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy. Ther Drug Monit 2008;30:60-66.
5. Brundage RC, Yong FH, Fenton T, Spector SA, Starr SE, and Fletcher CV: Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother 2004;48: 979-984.
6. Fraaij PL, van Kampen JJ, Burger DM, and de Groot R: Pharmacokinetics of antiretroviral therapy in HIV-1-infected children. Clin Pharmacokinet 2005;44:935-956.
7. Haas DW, Ribaudo HJ, Kim RB, et al.: Pharmacogenetics of efavirenz and central nervous system side effects: An adult AIDS clinical trials group study. AIDS 2004;18:2391-2400.
8. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, and Buclin T: Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1- infected patients. AIDS 2001;15:71-75. (Pubitemid 32055781)
9. Joly V and Yeni P: Non-nucleoside reverse transcriptase inhibitors. Ann Med Interne (Paris) 2000;151:260-267.
10. Fraaij PL, Rakhmanina N, Burger DM, and de Groot R: Therapeutic drug monitoring in children with HIV=AIDS. Ther Drug Monit 2004;26:122-126. (Pubitemid 38501204)
11. Hoody DW and Fletcher CV: Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children. Semin Pediatr Infect Dis 2003;14: 286-294.
12. King JR, Kimberlin DW, Aldrovandi GM, and Acosta EP: Antiretroviral pharmacokinetics in the paediatric population: A review. Clin Pharmacokinet 2002;41:1115-1133.
13. Stahle L, Moberg L, Svensson JO, and Sonnerborg A: Efavirenz plasma concentrations in HIV-infected patients: Interand intraindividual variability and clinical effects. Ther Drug Monit 2004;26:267-270.
14. Khoo SH, Lloyd J, Dalton M, et al.: Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)-a randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr 2006;41:461-467.
15. la Porte CJL, Back DJ, Blaschke T, et al.: Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antiviral Ther 2006;3:4-14.
16. Tsuchiya K, Gatanaga H, Tachikawa N, et al.: Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 2004;319:1322-1326.
17. Nyakutira C, Roshammar D, Chigutsa E, et al.: High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV=AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008;64:357-365.
18. Wang J, Sonnerborg A, Rane A, et al.: Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 2006;16:191-198.
19. Ren Y, Nuttall JJ, Egbers C, et al.: High prevalence of subtherapeutic plasma concentrations of efavirenz in children. J Acquir Immune Defic Syndr 2007;45:133-136.
20. Egge-Jacobsen W, Unger M, Niemann CU, et al.: Automated, fast, and sensitive quantification of drugs in human plasma by LC=LC-MS: Quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors. Ther Drug Monit 2004;26:546-562.
21. Koal T, Burhenne H, Romling R, Svoboda M, Resch K, and Kaever V: Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography=tandem mass spectrometry. Rapid Commun Mass Spectrom 2005;19: 2995-3001.
22. Back D, Gibbons S, and Khoo S: An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit 2006;28:468-473.
23. Joshi AS, Barret JS, Fiske WD, et al.: Population pharmacokinetics of efavirenz in phase II studies and relationships with efficacy. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 1999, San Francisco [Poster 1201].
24. Wintergerst U, Hoffmann F, Jansson A, et al.: Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. J Antimicrob Chemother 2008;61:1336-1339.
25. Puthanakit T, Tanpaiboon P, Aurpibul L, Cressey TR, and Sirisanthana V: Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIVinfected Thai children. Antivir Ther 2009;14:315-320.
26. Starr SE, Fletcher CV, Spector SA, et al.: Combination therapy with efavirenz, nelfinavir, and nucleoside reversetranscriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 team. N Engl J Med 1999;341:1874-1881.
27. von Hentig N, Koenigs C, Elanjikal S, et al.: Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines. Eur J Med Res 2006;11:377-380.
28. ter Heine R, Scherpbier HJ, Crommentuyn KML, et al.: A pharmacokinetic and pharmacogenetic study of efavirenz in children: Dosing guidelines can result in subtherapeutic concentrations. Antivir Ther 2008;13:779-787.